Kidney Function Tests Market Size, Share & Trends Analysis Report By Product (Clearance Tests, Urine Tests), By End Use (Hospitals, Diagnostic Laboratories, Research Laboratories And Institutes), By Region, And Segment Forecasts, 2021 - 2028

Report Overview

The global kidney function tests market size was valued at USD 777.06 million in 2020 and is expected to grow at a compound annual growth rate (CAGR) of 6.2% from 2021 to 2028. Factors, such as investments by market players, increasing R&D activities, high prevalence of kidney diseases, and rising government initiatives, are expected to significantly drive market growth. Kidney function tests are simple laboratory tests used for investigating and evaluating functions of the kidney. Increased risk of Chronic Kidney Disease (CKD) and Acute Kidney Injury (AKI) due to the rising prevalence of diabetes and hypertension has drastically upsurged the demand for these products. The outbreak of coronavirus has further fueled the product demand.

According to the study published by the National Kidney Foundation, people hospitalized due to Covid-19 are at significant risk of developing AKI. The study stated that Covid-19 patients were twice as likely to develop AKI as compared to non-Covid-19 patients. Health authorities recommended that Covid-19 patients who had an AKI should be tested regularly as their risk of developing CKD is higher than others. These factors will propel the kidney function tests market growth over the forecast period.

Rising R&D initiatives for the development of novel products are expected to significantly boost market growth during the forecast period. For instance, in January 2020, Germany-based SphingoTec GmbH launched its IB10 sphingotest penKid, a Point-of-Care (PoC) test for Proenkephalin (penKid). This biomarker enables real-time evaluation of kidney function with a normal blood test. In addition, growing investments in the field of kidney function testing are further expected to fuel the market growth. In January 2020, Sweden-based Elypta AB raised a seed round worth USD 7.0 million to develop the first urine test for kidney cancer.

Chronic kidney disease has become a global public health problem having a high economic cost associated with it. According to the National Institutes of Health (NIH), the global prevalence of CKD is around 14.0%. Also, the prevalence of CKD risk factors, such as diabetes, hypertension, and obesity, is on the rise owing to lifestyle changes. This has led to an increased demand for mandatory screening tests in patients with hypertension and diabetes for CKD, thus creating a high product demand. As per the data published by the International Diabetes Federation, in 2019, around 463.0 million adults had diabetes globally, which is predicted to reach 700 million by 2045.

Furthermore, several public-private organizations are undertaking initiatives to facilitate kidney disease testing in key regions. For instance, in July 2020, the National Kidney Foundation (NKF) in collaboration with the National Committee for Quality Assurance (NCQA), introduced a new kidney health evaluation measure, specifically for patients with diabetes. The new guidelines suggest routinely test of diabetes patients for kidney diseases. Such initiatives are anticipated to create a lucrative environment for market growth.

Product Insights

In 2020, the clearance tests segment accounted for the major market share of 28.73% and is expected to hold its dominance during the study period. Clearance tests are the gold standard for monitoring and measurement of glomerular filtration rate. These products include creatinine and inulin test, which provides an important addition to traditional diagnostic tests to obtain precise results. Moreover, these tests ensure that there is minimal variation in performance owing to their optimum sensitivity and precision. The low cost and easy availability of these products in the market lead to their increased adoption.

The urine tests segment is expected to register the fastest CAGR over the forecast period. This can be attributed to the wide array of applications of these products including detection of Urinary Tract Infections (UTIs), diabetes, high blood pressure, kidney stones, pregnancy, etc. Moreover, detection of prescription drug abuse, which can be done with the help of urine tests and an increase in PoC diagnostics coupled with the low cost of these tests are expected to boost the segment growth.

End-use Insights

The hospitals segment held the largest market share of 53.89% in 2020 and is projected to retain the leading position throughout the forecast period. This high share is attributed to increasing hospital visits due to the rising awareness about CKD and its treatment. Moreover, the development of sophisticated infrastructures across various regions, which help in performing efficient diagnostic procedures will contribute to the segment’s share.

Favorable reimbursement scenarios coupled with initiatives taken by healthcare organizations across the globe to promote the use of advanced diagnostic tests are also predicted to drive the segment. The diagnostic laboratories segment is also anticipated to account for a significant market share by 2028 as these labs are cost-effective, can conduct a large number of tests, and provide accurate results. The research laboratories and institutes segment is expected to register the fastest CAGR over the forecast period owing to increasing R&D activities in regions, such as North America and Europe.

Regional Insights

North America held the largest market share of 39.10% in 2020 and is expected to maintain its dominance throughout the study period on account of well-established healthcare infrastructure, high awareness levels about CKD, and favorable reimbursement policies & government initiatives. The U.S. accounted for the leading share in North America regional market. Key factors contributing to its dominance include the local presence of major market players and the easy availability of technologically advanced products.

Asia Pacific is projected to be the fastest-growing regional market over the forecast period due to the rapidly developing healthcare facilities and an increase in investments by leading market players. Furthermore, the presence of a large target population in emerging countries, such as China and India, is expected to drive the regional market during the forecast period. For instance, according to the data published by the NCBI, the overall prevalence of CKD in India is around 17.20%.

Key Companies & Market Share Insights

The key players operating in the market are adopting growth strategies, such as collaborations and partnerships, to expand their geographical reach. For instance, in September 2020, Baxter International, Inc. went under a strategic alliance with bioMérieux for the distribution of NEPHROCLEARTM CCL14 tests. Currently, under development, the NEPHROCLEARTM CCL14 test is designed to assess the chance of persistent severe AKI. Some of the key companies in the global kidney function tests market are:

• Abbott Laboratories

• Danaher Corporation (Beckman Coulter, Inc.)

• F. Hoffmann-La Roche

• Sysmex Corporation

• Siemens Healthineers

• Randox Laboratories

• Quest Diagnostics

• Acon Laboratories

• Nova Biomedical

• Laboratory Corporation of America Holdings (LabCorp)

Kidney Function Tests Market Report Scope

Segments Covered in the Report

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2016 to 2028. For the purpose of this study, Grand View Research has segmented the global kidney function tests market report on the basis of product, end-use, and region:

• Product Outlook (Revenue, USD Million, 2016 - 2028)

  • Clearance Tests

  • Urine Tests

  • Blood Tests

  • Dilution and Concentration Tests

  • Other Tests

• End-use Outlook (Revenue, USD Million, 2016 - 2028)

  • Hospitals

  • Diagnostic Laboratories

  • Research Laboratories and Institutes

  • Others

• Regional Outlook (Revenue, USD Million, 2016 - 2028)

  • North America

    • U.S.

    • Canada

  • Europe

    • U.K.

    • Germany

    • Spain

    • France

    • Italy

    • Russia

  • Latin America

    • Brazil

    • Mexico

    • Argentina

  • Asia Pacific

    • Japan

    • China

    • India

    • South Korea

    • Singapore

    • Australia

  • MEA

    • South Africa

    • Saudi Arabia

    • UAE